DB
NKGN

Dmitry Balyasny’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Dmitry Balyasny’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-310,359
Closed -$2.58M – 2986
2023
Q3 		$2.58M Hold
310,359
– – 0.01% 1314
2023
Q2 		$3.21M Sell
310,359
-389,641
-56% -$3.99M 0.01% 1216
2023
Q1 		$7.09M Hold
700,000
– – 0.02% 932
2022
Q4 		$6.96M Buy
700,000
+300,000
+75% +$2.96M 0.02% 885
2022
Q3 		$3.9M Hold
400,000
– – 0.01% 1144
2022
Q2 		$3.88M Hold
400,000
– – 0.01% 1059
2022
Q1 		$3.88M Hold
400,000
– – 0.01% 1061
2021
Q4 		$3.88M Hold
400,000
– – 0.01% 936
2021
Q3 		$3.88M Buy
+400,000
New +$3.9M 0.02% 916

Other funds holding NKGN

SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.21B AUM 13.69% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
UOC
University of Chicago Chicago, Illinois $420M AUM 42.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Dmitry Balyasny's NKGN Position: Q4 2023 in Review

Dmitry Balyasny sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q4 2023, closing a stake of 310,359 shares — an estimated $2.58M sold.

Dmitry Balyasny first reported a position in NKGN in Q3 2021 and held it in 9 quarters. The position peaked at $7.09M in Q1 2023. 9 funds tracked by Wall St. Rank hold NKGN as of Q4 2023.

  • Dmitry Balyasny reported no remaining NKGen Biotech, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Dmitry Balyasny sold 310,359 NKGen Biotech, Inc. Common Stock shares in Q4 2023, an estimated $2.58M.
  • Dmitry Balyasny first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 9 quarters.
  • Dmitry Balyasny's NKGen Biotech, Inc. Common Stock position peaked at $7.09M in Q1 2023.
  • 9 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q4 2023.

Based on Balyasny Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.